Towards Personalization in the Curative Treatment of Gastric Cancer
Authors:
Open Access
- 30 November 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.Keywords
This publication has 109 references indexed in Scilit:
- Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in ChinaJournal of Translational Medicine, 2013
- Advanced health biotechnologies in Thailand: redefining policy directionsJournal of Translational Medicine, 2013
- Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysisBritish Journal of Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Meta-analysis Shows That Prevalence of Epstein–Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic LocationGastroenterology, 2009
- Postoperative chemoradiotherapy in gastric cancer––a phase I–II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapyAnnals of Oncology, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapyBritish Journal of Cancer, 2007
- Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarrayJournal of Clinical Pathology, 2006